P M Barse1. 1. Cooper Cancer Institute, Cooper Health System, Voorhees, NJ, USA.
Abstract
OBJECTIVES: To provide a discussion of the treatment of metastatic breast cancer, nursing interventions, and quality of life issues for women with advanced breast cancer. DATA SOURCES: Journal articles and internet web sites. CONCLUSIONS: Advances in the discovery of new chemotherapeutic regimens, monoclonal antibodies, and bisphosphonates have offered more options for the treatment of metastatic breast cancer. Treatment is aimed at improving survival while maintaining quality of life. IMPLICATIONS FOR NURSING PRACTICE: Nurses can use this information to educate patients about their cancer treatment. It provides nurses with strategies for management of treatment side effects and will enhance their understanding of quality of life issues for women with metastatic breast cancer.
OBJECTIVES: To provide a discussion of the treatment of metastatic breast cancer, nursing interventions, and quality of life issues for women with advanced breast cancer. DATA SOURCES: Journal articles and internet web sites. CONCLUSIONS: Advances in the discovery of new chemotherapeutic regimens, monoclonal antibodies, and bisphosphonates have offered more options for the treatment of metastatic breast cancer. Treatment is aimed at improving survival while maintaining quality of life. IMPLICATIONS FOR NURSING PRACTICE: Nurses can use this information to educate patients about their cancer treatment. It provides nurses with strategies for management of treatment side effects and will enhance their understanding of quality of life issues for women with metastatic breast cancer.
Authors: Evie E M Kolsteren; Esther Deuning-Smit; Alanna K Chu; Yvonne C W van der Hoeven; Judith B Prins; Winette T A van der Graaf; Carla M L van Herpen; Inge M van Oort; Sophie Lebel; Belinda Thewes; Linda Kwakkenbos; José A E Custers Journal: Cancers (Basel) Date: 2022-08-11 Impact factor: 6.575
Authors: Simon Gebremeskel; Adam Nelson; Brynn Walker; Tora Oliphant; Lynnea Lobert; Douglas Mahoney; Brent Johnston Journal: J Immunother Cancer Date: 2021-03 Impact factor: 13.751